The global health and economic burden of chikungunya from 2011 to 2020: a model-driven analysis on the impact of an emerging vector-borne disease.

Autor:	de Roo AM; Valneva Austria GmbH, Vienna, Austria adrianne.deroo@gmail.com.; Department of Health Sciences, University of Groningen, Groningen, Netherlands., Vondeling GT; Valneva Austria GmbH, Vienna, Austria., Boer M; ASC Academics BV, Groningen, Groningen, Netherlands., Murray K; Department of Pediatrics, Emory University, Atlanta, Georgia, USA., Postma MJ; Department of Health Sciences, University of Groningen, Groningen, Groningen, Netherlands.; Department of Economics, Econometrics & Finance, University of Groningen, Groningen, Netherlands.; Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Badung, Indonesia.; Division of Pharmacology and Therapy, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia.
Jazyk:	angličtina
Zdroj:	BMJ global health [BMJ Glob Health] 2024 Dec 03; Vol. 9 (12). Date of Electronic Publication: 2024 Dec 03.
DOI:	10.1136/bmjgh-2024-016648
Abstrakt:	Introduction: Chikungunya is a mosquito-borne arboviral disease posing an emerging global public health threat. Understanding the global burden of chikungunya is critical for designing effective prevention and control strategies. However, current estimates of the economic and health impact of chikungunya remain limited and are potentially underestimated. This study aims to provide a comprehensive overview of the chikungunya burden worldwide. Methods: We analysed the global burden of chikungunya between 2011 and 2020 and calculated disability-adjusted life years (DALYs) and direct and indirect costs using a data-driven simulation model. The main outcomes were the number of cases, the total DALY burden, and the direct and indirect costs of acute and chronic chikungunya between 2011 and 2020. Results: Our study revealed a total of 18.7 million chikungunya cases in 110 countries between 2011 and 2020, causing 1.95 million DALYs. Most of this burden was found in the Latin American and Caribbean region. The total economic burden caused by chikungunya over these 10 years was estimated at $2.8 billion in direct costs and $47.1 billion in indirect costs worldwide. Long-term chronic illness was the source of most costs and DALYs. Conclusion: Chikungunya has a higher disease burden than was previously estimated and costs related to the disease are substantial. Especially in combination with its unpredictable nature, chikungunya could significantly impact local health systems. Insights from this study could inform decision makers on the impact of chikungunya on population health and help them to appropriately allocate resources to protect vulnerable populations from this debilitating disease. Competing Interests: Competing interests: AMR and GTV are Valneva employees and own stock options of Valneva. MB is an employee of ASC Academics. ASC Academics has received consultancy fees for this project from Valneva Austria GmbH. MJP reports grants and honoraria from various pharmaceutical companies, including those developing, producing, and marketing vaccines. He holds stocks in Health-Ecore (Zeist, Netherlands) and PAG BV (Groningen, Netherlands), and advises ASC Academics (Groningen, Netherlands). KOM serves on the Scientific Advisory Board for Valneva. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu